CYRX vs VTR
CYRX: Cryoport is the leading provider of end-to-end temperature-controlled supply chain solutions specifically built for cell and gene therapies, from preclinical development through global commercialization. VTR: Ventas is a leading healthcare REIT delivering value through a massive portfolio of senior housing, research, and outpatient medical facilities serving an aging population.
Side-by-side fundamentals
| Metric | CYRX | VTR | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $15.15 | $100.11 | |
| Market cap as of 2026-07-31 | $764M | $48.7B | |
| P/E as of 2026-07-31 | 10.05 | 175.37 | CYRX lower |
| PEG as of 2026-07-31 | n/a | 6.88 | |
| Net margin as of 2026-07-31 | +41.6% | +4.3% | CYRX higher |
| Gross margin as of 2026-07-31 | +47.2% | +40.7% | CYRX higher |
| Operating margin as of 2026-07-31 | -21.4% | +13.9% | VTR higher |
| ROE as of 2026-07-31 | +15.0% | +2.0% | CYRX higher |
| ROA as of 2026-07-31 | +9.9% | +1.0% | CYRX higher |
| Debt / equity as of 2026-07-31 | 0.38 | 0.93 | CYRX lower |
| Revenue growth (YoY) as of 2026-07-31 | -14.8% | +20.7% | VTR higher |
| Revenue CAGR (3y) SEC XBRL | -9.4% | +12.2% | VTR higher |
| Dividend yield as of 2026-07-31 | n/a | +2.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-31 | 1.89 | 0.71 | |
| 1-year return as of 2026-07-27 close | +93.0% | +50.6% | CYRX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.